Page last updated: 2024-11-13

fps-zm1

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

FPS-ZM1: a neuroprotective agent and RAGE receptor antagonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID24752728
CHEMBL ID4075936
SCHEMBL ID1169839
MeSH IDM0574281

Synonyms (27)

Synonym
S8185
945714-67-0
n-benzyl-4-chloro-n-cyclohexylbenzamide
SCHEMBL1169839
HY-19370
fps-zm1
CS-5270
AC-29968
4-chloro-n-cyclohexyl-n-(phenylmethyl)benzamide
fps zm1
J-523470
EX-A924
AKOS027422835
F17364
bdbm50249567
FT-0700419
BCP16845
fps zm1;fpszm1; fps-zm 1; fps zm-1; fpszm 1
Z1424714705
mfcd22378757
AS-47971
HMS3886N06
CCG-267784
CHEMBL4075936 ,
VMB71467
A916425
EN300-110349

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"Downregulation of abnormal Aβ influx across the BBB by FPS-ZM1 at higher dosage contributes to reduced neuronal apoptosis, improved hippocampal plasticity and cognitive impairment in db/db mice."( Targeted inhibition of RAGE reduces amyloid-β influx across the blood-brain barrier and improves cognitive deficits in db/db mice.
Chen, F; Du, YF; Hong, H; Hu, M; Long, Y; Reed, MN; Suppiramaniam, V; Tang, SS; Wang, H, 2018
)
0.73
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Advanced glycosylation end product-specific receptorHomo sapiens (human)Ki0.10700.02500.10700.2300AID1475145; AID1475152; AID1475153; AID1908570
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (46)

Processvia Protein(s)Taxonomy
response to hypoxiaAdvanced glycosylation end product-specific receptorHomo sapiens (human)
microglial cell activationAdvanced glycosylation end product-specific receptorHomo sapiens (human)
regulation of T cell mediated cytotoxicityAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of protein phosphorylationAdvanced glycosylation end product-specific receptorHomo sapiens (human)
inflammatory responseAdvanced glycosylation end product-specific receptorHomo sapiens (human)
cell adhesionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
cell surface receptor signaling pathwayAdvanced glycosylation end product-specific receptorHomo sapiens (human)
learning or memoryAdvanced glycosylation end product-specific receptorHomo sapiens (human)
response to woundingAdvanced glycosylation end product-specific receptorHomo sapiens (human)
glucose mediated signaling pathwayAdvanced glycosylation end product-specific receptorHomo sapiens (human)
neuron projection developmentAdvanced glycosylation end product-specific receptorHomo sapiens (human)
negative regulation of interleukin-10 productionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of chemokine productionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of interleukin-1 beta productionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of interleukin-12 productionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of interleukin-6 productionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of tumor necrosis factor productionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of heterotypic cell-cell adhesionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of activated T cell proliferationAdvanced glycosylation end product-specific receptorHomo sapiens (human)
transcytosisAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of JNK cascadeAdvanced glycosylation end product-specific receptorHomo sapiens (human)
astrocyte activationAdvanced glycosylation end product-specific receptorHomo sapiens (human)
regulation of synaptic plasticityAdvanced glycosylation end product-specific receptorHomo sapiens (human)
induction of positive chemotaxisAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of monocyte chemotactic protein-1 productionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
protein localization to membraneAdvanced glycosylation end product-specific receptorHomo sapiens (human)
regulation of spontaneous synaptic transmissionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
transport across blood-brain barrierAdvanced glycosylation end product-specific receptorHomo sapiens (human)
regulation of long-term synaptic potentiationAdvanced glycosylation end product-specific receptorHomo sapiens (human)
negative regulation of long-term synaptic potentiationAdvanced glycosylation end product-specific receptorHomo sapiens (human)
negative regulation of long-term synaptic depressionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
regulation of p38MAPK cascadeAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of p38MAPK cascadeAdvanced glycosylation end product-specific receptorHomo sapiens (human)
regulation of non-canonical NF-kappaB signal transductionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic processAdvanced glycosylation end product-specific receptorHomo sapiens (human)
negative regulation of blood circulationAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of endothelin productionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
response to amyloid-betaAdvanced glycosylation end product-specific receptorHomo sapiens (human)
cellular response to amyloid-betaAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of monocyte extravasationAdvanced glycosylation end product-specific receptorHomo sapiens (human)
regulation of CD4-positive, alpha-beta T cell activationAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of dendritic cell differentiationAdvanced glycosylation end product-specific receptorHomo sapiens (human)
regulation of inflammatory responseAdvanced glycosylation end product-specific receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (11)

Processvia Protein(s)Taxonomy
amyloid-beta bindingAdvanced glycosylation end product-specific receptorHomo sapiens (human)
transmembrane signaling receptor activityAdvanced glycosylation end product-specific receptorHomo sapiens (human)
scavenger receptor activityAdvanced glycosylation end product-specific receptorHomo sapiens (human)
protein bindingAdvanced glycosylation end product-specific receptorHomo sapiens (human)
signaling receptor activityAdvanced glycosylation end product-specific receptorHomo sapiens (human)
identical protein bindingAdvanced glycosylation end product-specific receptorHomo sapiens (human)
S100 protein bindingAdvanced glycosylation end product-specific receptorHomo sapiens (human)
protein-containing complex bindingAdvanced glycosylation end product-specific receptorHomo sapiens (human)
advanced glycation end-product receptor activityAdvanced glycosylation end product-specific receptorHomo sapiens (human)
molecular adaptor activityAdvanced glycosylation end product-specific receptorHomo sapiens (human)
laminin receptor activityAdvanced glycosylation end product-specific receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
fibrillar centerAdvanced glycosylation end product-specific receptorHomo sapiens (human)
extracellular regionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
plasma membraneAdvanced glycosylation end product-specific receptorHomo sapiens (human)
cell surfaceAdvanced glycosylation end product-specific receptorHomo sapiens (human)
apical plasma membraneAdvanced glycosylation end product-specific receptorHomo sapiens (human)
cell junctionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
postsynapseAdvanced glycosylation end product-specific receptorHomo sapiens (human)
plasma membraneAdvanced glycosylation end product-specific receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1475153Inhibition of HMGB1 binding to human RAGE domain V expressed in CHO cells2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective.
AID1908570Inhibition of amyloid beta binding to RAGE (unknown origin) transfected in CHO cells2022European journal of medicinal chemistry, Jun-05, Volume: 236Discovery of novel dual RAGE/SERT inhibitors for the potential treatment of the comorbidity of Alzheimer's disease and depression.
AID1475145Displacement of [I125]amyloid beta (1 to 40) from human RAGE domain V expressed in CHO cells2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective.
AID1475152Inhibition of S110B binding to human RAGE domain V expressed in CHO cells2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (48)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's29 (60.42)24.3611
2020's19 (39.58)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.58 (24.57)
Research Supply Index3.89 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index32.40 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (4.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other46 (95.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]